Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist,in Vitro and in Vivo

Atsuo Tahara, Yuichi Tomura, Koh-Ichi Wada, Toshiyuki Kusayama, Junko Tsukada, Masahiro Takanashi, Takeyuki Yatsu, Wataru Uchida and Akihiro Tanaka
Journal of Pharmacology and Experimental Therapeutics July 1997, 282 (1) 301-308;
Atsuo Tahara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuichi Tomura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koh-Ichi Wada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiyuki Kusayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junko Tsukada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Takanashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeyuki Yatsu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wataru Uchida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akihiro Tanaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The biochemical and pharmacological profile of YM087, 4′-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro andin vivo studies. YM087 showed high affinity for V1A receptors from rat liver and V2 receptors from rat kidney with Ki values of 0.48 and 3.04 nM, respectively. YM087 also inhibited [3H]oxytocin (OT) binding to rat uterus (OT receptors) plasma membranes with aKi value of 44.4 nM, and at 100 μM did not affect the binding of [3H]AVP to anterior pituitary (V1B receptors) plasma membranes, which indicated that it had less affinity for these OT and V1B receptors. YM087 had no effect on cytosolic free calcium concentration ([Ca++]i) itself, but suppressed AVP-induced increase in [Ca++]i of cultured vascular smooth muscle cells at the same concentrations as the binding affinities. Furthermore, YM087 potently blocked AVP-induced cAMP production of cultured renal epithelium cells concentration dependently and had no agonistic activities. In in vivo studies, intravenous administration of YM087 inhibited the pressor response to exogenous AVP in pithed rats and produced an aquaretic effect in dehydrated conscious rats in a dose-dependent manner. These results demonstrate that YM087 is a potent and nonpeptide dual AVP V1A and V2 receptors antagonist and can be used in future studies to help clarify the physiological and pathophysiological roles of AVP.

Footnotes

  • Send reprint requests to: Atsuo Tahara, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan.

  • Abbreviations:
    AVP
    8-arginine vasopressin
    OT
    oxytocin
    YM087
    4′-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride
    OPC-21268
    1-{1-[4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl}-3,4-dihydro-2(1H)-quinolinone
    OPC-31260
    5-dimethylamino-1-{4-(2-methylbenzoylamino)benzoyl}-2,3,4,5-tetrahydro-1H-benzazepine
    d(CH2)5Tyr(Me)AVP
    [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin (SKF-100273)
    dDAVP
    1-desamino-8-d-arginine-vasopressin (desmopressin)
    d(CH2)5-d-Tyr(Et)VAVP
    [1-(β-mercapto-β,β-cyclopentamethylenpropionic acid)-d-Tyr(O-ethyl)-4-valine]-vasopressin
    PLC
    phospholipase C
    EGTA
    ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
    IBMX
    3-isobutyl-1-methylxanthine
    DMEM
    Dulbecco’s modified Eagle’s medium
    FCS
    fetal calf serum
    BSA
    bovine serum albumin
    HEPES
    N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
    CHF
    congestive heart failure
    • Received January 6, 1997.
    • Accepted March 10, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 1
1 Jul 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist,in Vitro and in Vivo
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist,in Vitro and in Vivo

Atsuo Tahara, Yuichi Tomura, Koh-Ichi Wada, Toshiyuki Kusayama, Junko Tsukada, Masahiro Takanashi, Takeyuki Yatsu, Wataru Uchida and Akihiro Tanaka
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 301-308;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist,in Vitro and in Vivo

Atsuo Tahara, Yuichi Tomura, Koh-Ichi Wada, Toshiyuki Kusayama, Junko Tsukada, Masahiro Takanashi, Takeyuki Yatsu, Wataru Uchida and Akihiro Tanaka
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 301-308;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antagonism of an Adenosine/ATP Receptor in FollicularXenopus Oocytes
  • Toxin and Subunit Specificity of Blocking Affinity of Three Peptide Toxins for Heteromultimeric, Voltage-Gated Potassium Channels Expressed in Xenopus Oocytes
  • Inhibition of Voltage-Dependent Sodium Channels by the Anticonvulsant γ-Aminobutyric Acid Type A Receptor Modulator, 3-Benzyl-3-Ethyl-2-Piperidinone
Show more CELLULAR AND MOLECULAR PHARMACOLOGY

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics